공지사항

Tumor Treating Fields Mesothelioma

Tumor treating fields mesothelioma diagnosis and treatment, a brand new type of therapy, uses alternating electric field to slow the growth of cancer. It is often used in conjunction with chemotherapy to treat the pleural cancer.

After the successful STELLAR study, the FDA approved TTFields in conjunction with pemetrexed cisplatin and the year 2019 saw the FDA approved TTFields. Patients can consult their physician for this treatment.

Disrupting Cell Division

TTFields utilizes alternating electrical fields that disrupt cancer cell protein and prevent the cells from dividing. This can stop mesothelioma from expanding or forming in other organs. TTFields also work to stimulate the production of proteins that can destroy cancerous cells and help the immune system fight mesothelioma tumors.

During treatment, the patient wears a small device with insulated pads that stick to the skin. The device delivers low-intensity electric current, Tumor treating fields mesothelioma and patients can regulate the amount of treatment they receive. A mesothelioma therapy session lasts approximately 30 minutes. Patients can have TTFields treatment several times per day.

A TTFields 2021 study found that electrical fields ranging from 100 to 300 kilohertz were able to stop the growth of cancer cells and trigger their death. The study covered different kinds of cancer cells, and discovered that electrical fields killed all of them, regardless of cell's structure.

The study's author recommended the use of TTFields and chemotherapy for mesothelioma. Novocure's TTFields product, called NovoTTF 100L, was approved by the FDA in the year 2019 to treat unresectable pleural mesothelioma. It is now available from mesothelioma specialists from certified medical centers in the U.S. including the West Cancer Center, Memphis. The NovoTTF 100L device, also referred to as Optune Lua has been used in the treatment of abdominal mesothelioma treatment when it is combined with platinum-based chemotherapy and pemetrexed. Mesothelioma patients have reported longer survival when the TTFields therapy is paired with chemotherapy.

Another study published in "Lung Cancer", reported that TTFields therapy is effective with chemotherapy. Researchers discovered that combining chemotherapy with TTFields significantly reduced the amount of mesothelioma tumors that are malignant in animal models. The study also revealed that the combination of these two treatments increased the production of proteins that kill mesothelioma cancer cells and reduce the amount cancerous DNA that is found in the body.

Although it is an emerging treatment, a lot of mesothelioma specialists do not yet offer TTFields to treat pleural mesothelioma. However, patients may be able to access this treatment option through clinical trials or mesothelioma alternative treatments centers that are certified by Novocure.

Stalling Tumor Development

Mesothelioma develops when mesothelial cells change and outlive their normal lifespan, leading to an overabundance of cancerous cells that multiply and spread in the body. The treatment of mesothelioma fields stops tumors from growing and spreading by stopping mesothelial cells from replicating.

The TTFields device is worn on the chest as the vest, and creates a series of electrical fields that can destroy proteins, kill cancer cells, and slow down tumor growth. The device comes with an insulated pad that sticks to the skin and can be used at home by patients or by health professionals trained by Novocure.

Doctors suggest combining TTFields therapy with chemotherapy for the best results. The combination increases the production of proteins that kill cancer cells and decreases the ability of cancer cells to repair DNA damage caused by chemotherapy drugs. This makes chemotherapy drugs perform even more effectively and increases survival rates in mesothelioma.

In the recent STELLAR trial, a combination of TTFields therapy and chemotherapy significantly increased survival in mesothelioma victims. The FDA approved the NovoTTF 100L System that is now sold as Optune Lua, for use alongside pemetrexed and carboplatin or cisplatin as the first-line treatment for malignant pleural mesothelioma in 2019.

Researchers have discovered that TTFields therapy works against mesothelioma by interrupting cell division. The treatment TTFields induces cancer cells to break apart in a process known as mitosis. The cellular debris gets trapped in surrounding tissues, which hinders the development of new tissues. Mitosis blocks mesothelioma cancer cells from repair of damaged genetic material, and makes them more susceptible to radiation treatment.

The TTFields treatment may also reduce tumor blood flow by suppressing vascular endothelial growth factor, also known as VEGF, as well as increasing hypoxia-inducible factor-1 beta, or HIF-1a. This is associated with cancer cell angiogenesis.

If you've been diagnosed with mesothelioma, talk to your physician about whether TTFields is right for you. Many mesothelioma specialists are working with Novocure on clinical trials to determine the efficacy of this revolutionary treatment. Contact a Novocure certified specialist at one of the more than 1,300 U.S. Treatment Centers to learn more about mesothelioma natural treatment treatments with TTFields.

Killing Tumor Cells

Tumor-treating fields for treating tumors (TTFields) disrupt cell division by sending electrical waves through the body to destroy tumor cells. They are low-intensity and medium frequency electrical fields that alternatingly target cancerous cells without harming healthy ones. These electric fields reduce DNA repair, and also boost cell defences, making cancerous cells more difficult to survive. TTF is non-invasive and has only mild adverse effects.

Scientists think TTFields are responsible for preventing mitosis, which is the process through which the cell divides into two identical new cells. Normal cells have control mechanisms that limit the process of mitosis, but malignant cancerous cells override this control and grow in a rapid rate. TTFields interferes with this process by blocking signals that control mitosis in mesothelioma cancer cells. In the STELLAR trial TTFields in combination with chemotherapy improved survival rates for mesothelioma. Mesothelioma patients who received TTFields along with maintenance cycles of chemotherapy lived six months longer on average than those who only received chemotherapy.

In a separate study it was found that TTFields can boost the effectiveness of certain chemotherapy drugs, also known as platinum-based treatments. These platinum-based therapies destroy mesothelioma through targeting mitochondria. This is where the energy of cancerous cells comes from. When TTFields is used in conjunction with these chemotherapies, the combination could result in higher levels DNA damage and faster death of cancer cells.

TTFields may also boost the effects of radiation therapy in certain cases. Scientists have observed that mixing TTFields with radiation therapy could cause a "synergistic effect." This means that the combination treatments increase the sensitivity of mesothelioma tumor cells to radiation.

Currently, TTFields is only available in certain mesothelioma centres. A mesothelioma doctor will determine if you're qualified for this treatment. If you are eligible, a lawyer for mesothelioma can help you access treatment that includes TTFields with chemotherapy. If you're an active military veteran mesothelioma lawyer will assist you in obtaining treatment that is covered by your VA health benefits.

Side Effects

The TT fields therapy disrupts the cancer cells by creating an electric field that hinders their ability to divide. This could slow the growth of tumors and stop the spread of cancer to other areas of the body. The TT fields device is non-invasive, which means it does not damage the surrounding tissue or cause discomfort. This is different from conventional chemotherapy, which requires injections into the vein or radiation, both of which can cause severe side effects.

In a study that included patients who received a combination of TT fields and temozolomide showed survival improvements similar to those who were treated with chemo on their own. Doctors attributing this improvement in survival to TT fields, which enhance the efficacy of chemo while reducing side effects.

Mesothelioma cancer cells can transform into cancerous cells and replicate in uncontrolled ways to create an aggressive tumor that takes over the organs of your body. Mesothelioma treatment such as TT fields stops mesothelioma from reproducing and hindering the body's normal functions by stopping cell division.

In a mesothelioma-related study patients who received TT fields together with chemotherapy had an average survival of 18.2 months. Patients who received TT fields, but not chemo had a survival rate of 12.1.

Tumor-treating fields are applied to the pleura or the thin lining that covers your lungs, on your abdomen or chest wall. The device is small and can be worn for 18 hours a day even during sleep time. This allows patients to maintain their lives and work while undergoing treatment.

TT fields can be added to traditional chemotherapy, immunotherapy, or other mesothelioma treatment. Patients with mesothelioma who are interested in TT fields should discuss this possibility with their mesothelioma specialist who can provide the eligibility requirements and benefits for the patient's individual situation.